Ketesse tablets

Marketed by Ferron Par Pharmaceuticals

Ingredients in every tablet

Dexketoprofen 25 mg

Each package contains

5 strips of 10 tablets

Other details

Dosage form:Tablet; coated
Flavour: None

W.H.O. classification

ATC Level 1: N - Nervous system
ATC Level 2: N02 - Analgesics
ATC Level 3: N02B - Other Analgesics and Antipyretics in ATC

Warnings

Pregnancy

NOT SAFEThis item is not safe for use during pregnancy.

Lactation

NOT SAFEThis item is not safe for use during lactation.

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

NOT SAFEThis item should not be used while operating heavy machinery.

Available in

Indonesia

Dosage information

0 TO 18 YEARS OLD
The safety and efficacy Ketesse in children have not been established and the product should not be used in children.

Ketesse film-coated tablet are not intended for long term use and the treatment must be limited to the symptomatic period.

18 TO 65 YEARS OLD
According to the nature and severity of pain, the recommended dosage is generally 12.5 mg every 4-6 hours or 25 mg every 8 hours.

Ketesse film-coated tablet are not intended for long term use and the treatment must be limited to the symptomatic period.

65 YEARS OLD AND ABOVE
It is recommended to start the therapy at the lower end of the dosage range (50 mg total daily dose). The dosage may be increased to that recommended for the general population only after good general tolerance has been ascertained.

Ketesse film-coated tablet are not intended for long term use and the treatment must be limited to the symptomatic period.

OTHER DETAILS
Hepatic dysfunction:
Patients with mild to moderate hepatic dysfunction should start therapy at reduced doses (50 mg total daily doses) and be closely monitored. Ketesse film-coated tablet should not be used in patients with severe hepatic dysfunction. (IPHA p.2,3, PI Ketesse, SPC p.1)

Renal dysfunction:
The initial dosage should be reduced to 50 mg total daily dose in patients with mildly impaired renal function. Ketesse film-coated tablet should not be used in patients with moderate to severe renal dysfunction. (IPHA p.3, PI Ketesse, SPC p.1)

Indication

Treatment of pain symptoms with mild to moderate intensity e.g. acute musculoskeletal pain, dysmenorrhea, dental pain and postoperative pain. (IPHA p.2, Medscape p.1, PI Ketesse, Product Monograph-2 p.48, Product Profile Tablet p.35, SPC p.1)

Disclaimer

The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for informational purposes only. This tool may not cover all possible drug interactions or all warnings or alerts. Please check with a physician if you have health questions or concerns about interactions or go to the appropriate government authority for a comprehensive list of medical warnings. Although we attempt to provide accurate and up-to-date information, no guarantee is made to that effect.

All of the content present on this website, including written text, photographs, videos, graphics, and other resources we might include (these will fall under the collective term of “website”), is meant to educate and should not be perceived as a substitution for professional medical advice, diagnosis or treatment. You should not resort to the website information to arrive at a diagnosis or treatment solution for your health problems or various medical conditions. It does not replace medical care, provided by a medical specialist. In the situation, you have specific symptoms and you might suspect that you are suffering from a medical problem, it is for the best to consult your physician.